A major IPO can be expected to attract a lot of new attention (and capital) to the psychedelic drug industry.
The Psychedelics Revolution. One part changing social attitudes. One part medical necessity. One part hard economics.
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
In a "bad" year for the emerging cannabis industry, global cannabis sales rose by 48% in 2019. That's not bad.
The largest U.S.-based cannabis company and the largest Canadian cannabis company have both seen their stock make strong moves. Will other cannabis companies follow?
As the U.S. Cannabis Revolution unfolds, over 90% of Americans now want cannabis legalized (at least) for medical purposes. Attention Congress.
2019 will be remembered as a bad year for cannabis investing. But there were also several important highlights this year that could set the stage for an epic rally -- next year.